Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XP21279 BL2 and Sinemet in Parkinson's Disease Subjects With Motor Fluctuations.

Next Previous
Trial Profile

A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XP21279 BL2 and Sinemet in Parkinson's Disease Subjects With Motor Fluctuations.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 May 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XP 21279 (Primary) ; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors XenoPort

Most Recent Events

  • 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
  • 05 Dec 2011 Primary endpoint 'Off-time' has not been met, according to a XenoPort media release.
  • 04 Aug 2011 Top-line results are expected by the end of 2011, according to a XenoPort media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top